Cow’s Milk Protein Allergy

牛奶蛋白过敏
  • 文章类型: Journal Article
    奶牛的牛奶蛋白过敏(CMPA)影响2%-7%的婴儿,并采用低过敏性配方进行管理。2022年召回婴儿配方奶粉,原因包括污染导致特殊配方奶粉短缺,强调CMPA管理挑战。了解医疗保健提供者(HCP)在短缺期间过渡到替代方案的决策至关重要。对儿科医师如何做出这些选择的关注有限。
    本研究利用美国HCP去识别调查数据来评估在短缺期间转换广泛水解配方时的驱动因素。
    104个合格的HCP参加了,包括普通儿科,儿科过敏/免疫学,和儿科胃肠病专家。安全,耐受性,疗效被确定为转换配方的首要因素。公式1被认为是耐受性良好的,患者接受,所有HCP都是安全的。大多数人对F1的安全性和有效性表示了强烈的信念。
    发现在短缺期间通知CMPA管理层,为HCP选择合适的配方和加强婴儿护理提供指导。
    UNASSIGNED: Cow\'s milk protein allergy (CMPA) affects 2%-7% of infants and is managed with hypoallergenic formulas. The 2022 recalls of infant formulas due to factors including contamination led to specialty formula shortages, highlighting CMPA management challenges. Understanding healthcare providers\' (HCPs) decision-making in transitioning to alternative formulas during shortages is crucial. Limited attention has been given to how pediatric physicians make these choices.
    UNASSIGNED: This study utilized US HCPs\' de-identified survey data to assess driving factors when switching extensively hydrolyzed formulas during shortages.
    UNASSIGNED: 104 eligible HCPs participated, including general pediatrics, pediatric allergy/immunology, and pediatric gastroenterology specialists. Safety, tolerability, and efficacy were identified as top factors for switching formulas. Formula 1 was considered well-tolerated, patient-accepted, and safe by all HCPs. Most expressed strong belief in Formula 1\'s safety and effectiveness.
    UNASSIGNED: Findings inform CMPA management during shortages, offering guidance to HCPs for suitable formula selection and enhanced infant care.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    2022年,由于全球供应链危机和大规模的国内配方奶粉召回,美国经历了全国婴儿配方奶粉短缺。关于配方短缺期间医疗保健提供者(HCP)临床决策的现有文献是有限的。本研究旨在分析在前所未有的国家配方奶粉短缺期间,在24个月以下婴儿管理牛乳蛋白过敏(CMPA)的氨基酸配方(AAF)之间切换时,影响儿科HCP临床决策的因素。
    该研究包括儿科HCP,在2022年1月至2022年11月的配方奶粉短缺期间,在24个月以下的婴幼儿中管理CMPA的经验。使用实时移动数据收集工具对儿科HCP进行了一项包括26个问题的去识别调查,这些问题检查了临床决策中使用的驱动因素。
    在接受调查的儿科HCP(n=75)中,切换到另一个AAF时,最常被认为是“极其重要”的因素包括安全性(85%),耐受性(73%),和疗效(83%)。在列出的四个AAF的检查因子中,HCP评级没有发现统计学上的显着差异。当比较四种AAF时,特定配方的可用性是在儿科HCP中表现出统计学上显着差异的唯一因素(p<0.05)。
    这项研究阐明了在2022年配方短缺期间影响儿科HCP选择用于CMPA管理的AAF的关键方面。这些发现强调了安全的重要性,耐受性,功效,以及儿科HCP决策过程中的可用性。
    UNASSIGNED: In 2022, the United States experienced a national shortage of infant formula due to a global supply chain crisis and a large-scale domestic formula recall. The existing literature on healthcare providers\' (HCPs) clinical decision-making during formula shortages is limited. This study aims to analyze the factors influencing pediatric HCP clinical decision-making when switching between amino acid formulas (AAF) for managing cow\'s milk protein allergy (CMPA) in infants under 24 months of age during an unprecedented national formula shortage.
    UNASSIGNED: The study included pediatric HCPs with experience managing CMPA in infants and toddlers under 24 months during the formula shortage from January 2022 to November 2022. A de-identified survey comprising 26 questions examining driving factors used in clinical decision-making was administered to pediatric HCPs using a real-time mobile data collection tool.
    UNASSIGNED: Among the surveyed pediatric HCPs (n = 75), the factors most frequently considered as \"extremely important\" when switching to another AAF included safety (85%), tolerability (73%), and efficacy (83%). No statistically significant differences were found in HCP ratings among the listed examined factors of the four AAFs. The availability of specific formulas was the only factor that exhibited a statistically significant difference in perceived performance among pediatric HCPs when comparing the four AAFs (p < 0.05).
    UNASSIGNED: This study elucidates the crucial aspects that influenced pediatric HCPs\' selection of AAFs for CMPA management during the 2022 formula shortage. The findings highlight the significance of safety, tolerability, efficacy, and availability in the pediatric HCP decision-making processes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    牛乳蛋白过敏(CMPA)是儿童早期最常见的食物过敏。对于那些需要母乳替代品的婴儿,广泛水解蛋白(EHF)的配方,应该是治疗的选择。由于有限的数据显示新诊断为CMPA的婴儿的初始症状进展,这些婴儿接受EHF治疗并添加合生元,这项研究的主要目的是评估治疗4周后所述婴儿的症状缓解情况.作为次要目的,本研究旨在评估治疗对家庭生活质量的影响。
    观测,纵向,prospective,和多中心的真实世界证据研究。干预阶段(EHF与合生元)持续28天,由65名患者完成。治疗医生注册了孩子的人体测量学,在基线和治疗28天后的婴儿胃肠道症状问卷(IGSQ-13)和CoMiSS(牛乳过敏症状评分)。治疗期间,看护人报告了孩子的反流和大便,PO-SCORAD(以患者为导向的特应性皮炎评分)和FAQL-PB(家庭生活质量-父母负担)。使用GoogleForms收集数据,并通过STATA程序进行分析。
    95.4%的患者在治疗4周后表现出总体初始症状的改善或消失。92%的患者胃肠道症状改善或消失(p<0.05),而87.5%的患者皮肤症状改善或消失(p<0.05)。基线时的中位数CoMiSS为9,其中21名患者超过12的截止点。治疗4周后,中位数降至3,无患者超过12截止点(p=0.000).在基线,患者的PO-SCORAD为11.5(四分位距1-23),在第28天达到1.0(四分位距1-6)(p=0.000).治疗减少大便频率(p<0.05),改善CMPA婴儿的粪便稠度(p=0.004)并降低反流频率(p=0.01)。在第28天,不再有任何反流发作的患者百分比从11%增加到31%(p=0.003)。在基线,13%的患者每天哭3小时以上,而在第28天,这一百分比下降到3%(p=0.03)。婴儿睡眠模式的改善也受到了赞赏。在研究开始时,56%的家庭报告感到非常不知所措,治疗28天后下降到17%(p<0.05)。一小部分在研究开始时没有感到不知所措的家庭(17%),在第28天增长到43%(p<0.05)。
    将EHF与合生元一起用于诊断或怀疑患有CMPA的婴儿的管理,表明安全性良好,足够的婴儿成长,和整体的改进,胃肠,和皮肤病学症状。它还表明每天反流和大便的频率较低,以及粪便稠度的改善,睡眠模式,以及婴儿及其家人的生活质量。
    UNASSIGNED: Cow\'s milk protein allergy (CMPA) is the most frequent food allergy in early childhood. For those infants requiring breastmilk substitutes, formulas with extensively hydrolyzed proteins (EHF), should be the treatment of choice. As there are limited data showing the progression of initial symptoms in infants newly diagnosed with CMPA who are treated with EHF with added synbiotics, the main objective of this study was to evaluate the resolution of symptoms in said infants after 4 weeks of treatment. As a secondary objective this study aimed to assess the impact of the treatment on the family\'s quality of life.
    UNASSIGNED: observational, longitudinal, prospective, and multicentric real-world evidence study. The intervention phase (EHF with synbiotics) lasted 28 days and was completed by 65 patients. Treating physicians registered child´s anthropometry, Infant Gastrointestinal Symptoms Questionnaire (IGSQ-13) and CoMiSS (Cow´s Milk Allergy Symptoms Score) both at baseline and after 28 days of treatment. During treatment, caregivers reported child´s regurgitation and stools, PO-SCORAD (Patient Oriented Scoring of Atopic Dermatitis) and FAQL-PB (Family Quality of Life-Parental Burden). Data were collected using Google Forms and analyzed through the STATA program.
    UNASSIGNED: 95.4% of the patients showed an improvement or disappearance of the overall initial symptoms after 4 weeks of treatment. Gastrointestinal symptoms improved or disappeared in 92% of patients (p < 0.05) while dermatological symptoms improved or disappeared in 87.5% of patients (p < 0.05). The median CoMiSS at baseline was 9, with 21 patients exceeding the cut-off point of 12. After 4 weeks of treatment, the median dropped to 3, and no patient exceeded the 12-cut-off point (p = 0.000). At baseline, patients had a PO-SCORAD of 11.5 (interquartile range 1-23) that went to 1.0 (interquartile range 1-6) at day 28 (p = 0.000). The treatment diminished stool frequency (p < 0.05), improved stool consistency (p = 0.004) and decreased the frequency of regurgitation in infants with CMPA (p = 0.01). The percentage of patients who no longer had any episode of regurgitation increased from 11% to 31% on day 28 (p = 0.003). At baseline, 13% of patients cried more than 3 h per day, while at day 28 that percentage dropped to 3% (p = 0.03). An improvement in the infants\' sleep pattern was also appreciated with the treatment. At study onset, 56% of the families reported feeling very overwhelmed, a percentage that dropped to 17% after 28 days of treatment (p < 0.05). The small percentage of families who did not feel overwhelmed at study onset (17%), grew to 43% on day 28 (p < 0.05).
    UNASSIGNED: The use of an EHF with synbiotics for the management of infants diagnosed with or suspected to have CMPA suggested a good safety profile, an adequate infant growth, and improvement of overall, gastrointestinal, and dermatological symptoms. It also suggested a lower daily frequency of regurgitations and stools, and an improvement in stool consistency, sleeping pattern, and quality of life of the infant and his family.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    牛奶蛋白过敏(CMPA)的管理可能因负责患者随访的临床医生的经验和专业领域而异,这可能与最近出版的文献一致,也可能不一致。为了分析西班牙儿科医生对此主题的观点,进行了一项调查。该调查旨在确定222名初级保健和医院儿科医生对CMPA预防和营养管理的当前意见和态度。参与的儿科医生填写了问卷,提供他们日常临床实践的见解,包括进入测试,对CMPA诊断各个方面的态度,预防,口腔食物挑战,和治疗。研究结果表明,儿科医生普遍同意使用广泛水解配方(eHFs)来预防高危特应性儿童的CMPA,尽管支持广泛使用这种做法的证据有限。然而,关于用益生元和益生菌加速耐受性发展的配方的实用性缺乏共识。在大多数情况下,儿科医生更喜欢eHFs用于CMPA的营养管理,其次是水解大米配方(HRFs),基于氨基酸的配方(AAF)是第三种选择。某些问题在儿科医生中仍然存在争议,如预防方法,症状评估,和益生菌的作用。管理方法的这些变化反映了临床医生经验和专业知识领域的影响,强调在这一领域需要标准化的指导方针。
    Management of cow\'s milk protein allergy (CMPA) can vary depending on the experience and area of expertise of the clinician responsible for the patient\'s follow-up, which may or may not align with the recently published literature. To analyze the perspectives of Spanish pediatricians on this topic, a survey was conducted. The survey aimed to determine the current opinions and attitudes of 222 primary care and hospital pediatricians toward CMPA prevention and nutritional management. Participating pediatricians completed the questionnaire, providing insights into their daily clinical practices, including access to testing, attitudes with respect to various aspects of CMPA diagnosis, prevention, oral food challenges, and treatment. The findings revealed that pediatricians generally agree on the use of extensively hydrolyzed formulas (eHFs) to prevent CMPA in high-risk atopic children, despite limited evidence supporting the widespread use of this practice. However, consensus was lacking regarding the utility of formulas with prebiotics and probiotics for expediting tolerance development. In most cases, pediatricians preferred eHFs for the nutritional management of CMPA, followed by hydrolyzed rice formulas (HRFs), with amino-acid-based formulas (AAFs) being the third option. Certain issues remained controversial among pediatricians, such as prevention methods, symptom assessment, and the role of probiotics. These variations in management approaches reflect the influence of clinician experience and area of expertise, underscoring the need for standardized guidelines in this field.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    为了评估增长,牛奶蛋白过敏(CMPA)婴儿使用基于广泛水解酪蛋白的配方(eHCF)的耐受性和安全性结果。
    总共226名婴儿(平均±SD年龄:106.5±39.5天,52.7%是女孩)接受eHCF的CMPA患者占每日饮食摄入量的至少一半。人体测量数据[年龄体重(WFA),在基线(第1次访视)记录长度(LFA)和长度体重(WFL)z评分],而关于婴儿喂养和粪便记录的数据,在第2次访视(第15±5天)和第3次访视(第30±5天)记录人体测量学和婴儿喂养方式以及配方满意度问卷。
    从基线到第2次和第3次就诊,WFAz评分(第2次就诊时从-0.60±1.13到-0.54±1.09,第3次就诊时从-0.44±1.05,p<0.001)和WFLz评分(第2次就诊时从-0.80±1.30到-0.71±1.22,第3次至-0.64±1.13至少有一半的婴儿从未经历过烦躁或拒绝喂养(55.7%)和喂养后吐口水(50.2%)。大多数母亲对研究配方感到满意(93.2%),并希望继续使用它(92.2%)。
    总而言之,eHCF在预期使用年龄≤6个月的CMPA婴儿人群中得到了良好的接受和耐受,并在使用后30天内实现了足够的体积消耗和改善的生长指数,同时具有良好的胃肠道耐受性和高水平的父母满意度。
    UNASSIGNED: To evaluate growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula (eHCF) in infants with cow\'s milk protein allergy (CMPA).
    UNASSIGNED: A total of 226 infants (mean ± SD age: 106.5 ± 39.5 days, 52.7% were girls) with CMPA who received eHCF comprising at least half of the daily dietary intake were included. Data on anthropometrics [weight for age (WFA), length for age (LFA) and weight for length (WFL) z-scores] were recorded at baseline (visit 1), while data on infant feeding and stool records, anthropometrics and Infant Feeding and Stool Patterns and Formula Satisfaction Questionnaires were recorded at visit 2 (on Days 15 ± 5) and visit 3 (on Days 30 ± 5).
    UNASSIGNED: From baseline to visit 2 and visit 3, WFA z-scores (from -0.60 ± 1.13 to -0.54 ± 1.09 at visit 2, and to -0.44 ± 1.05 at visit 3, p < 0.001) and WFL z-scores (from -0.80 ± 1.30 to -0.71 ± 1.22 at visit 2, and to -0.64 ± 1.13 at visit 3, p = 0.002) were significantly increased. At least half of infants never experienced irritability or feeding refusal (55.7%) and spit-up after feeding (50.2%). The majority of mothers were satisfied with the study formula (93.2%), and wished to continue using it (92.2%).
    UNASSIGNED: In conclusion, eHCF was well-accepted and tolerated by an intended use population of infants  ≤ 6 months of age with CMPA and enabled adequate volume consumption and improved growth indices within 30 days of utilization alongside a favorable gastrointestinal tolerance and a high level of parental satisfaction.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    早发性牛乳蛋白过敏和特应性皮炎在生命最初几个月的发展是多因素的,包括遗传和营养方面。本研究旨在评估不同喂养方式对牛奶蛋白过敏发生率的影响,特应性皮炎,和有家族过敏史的婴儿的成长。从3个欧洲国家随机招募了551名高危婴儿,采用三种喂养方式:纯母乳喂养,部分水解配方,或标准配方与完整的蛋白质完全或补充母乳喂养。在干预的前6个月,在有特应性皮炎家族史的婴儿中,6.5%的部分水解配方喂养的婴儿和22.7%的纯母乳喂养的婴儿(p=0.007)分别出现特应性皮炎。通过体重增加评估的生长在上述组之间没有差异。尽管在整个队列中,牛奶蛋白过敏与不同的牛奶喂养方案无关,当调整高母乳摄入量时,在食用部分水解配方奶粉的婴儿中,各自的事件显着降低(p<0.001)。该数据表明,与高风险婴儿的标准完整蛋白质配方相比,特定的部分水解配方可以作为母乳的更合适的补充。减少特应性皮炎的发生率。
    The development of early-onset cow\'s milk protein allergy and atopic dermatitis during the first months of life is multifactorial, including both genetic and nutritional aspects. This study aims to assess the impact of different feeding patterns on the incidence of cow\'s milk protein allergy, atopic dermatitis, and growth among infants with a family history of allergy. A total of 551 high-risk infants were randomly recruited from 3 European countries in three feeding regimens: exclusive breastfeeding, partially hydrolyzed formula, or standard formula with intact protein either exclusively or supplementary to breastfeeding. During the first 6 months of intervention, amongst infants with a family history of atopic dermatitis, 6.5% of partially hydrolyzed formula-fed infants and 22.7% of exclusively breastfed infants (p = 0.007) presented with atopic dermatitis respectively. Growth as assessed by weight increase did not differ between the aforementioned groups. Although cow\'s milk protein allergy was not related to the different milk feeding regimens in the whole cohort, when adjusting for high breast milk intake, the respective incident was significantly lower in the infants consuming partially hydrolyzed formula (p < 0.001). This data indicates that a specific partially hydrolyzed formula could serve as a more appropriate complement to breast milk compared to a standard intact protein formula in high-risk infants, to reduce the incidence of atopic dermatitis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    伴有拇指和血小板计数低的双侧放射状发育不全是血小板减少症候群的主要特征。这是一种不寻常的出生障碍,发病率为0.42\100.000人口。
    作者报告了一例6个月大的女婴,在6个月大的时候首次出现血小板减少症,由于牛奶被引入45天的慢性腹泻和生长障碍。她的手轴横向偏离了,和双侧半径缺失,两个拇指都存在。此外,她有异常的精神运动发育,marasmus案例表现。
    我们发布当前病例报告的目的是,照顾血小板减少症患者的临床医生将意识到各种并发症,这可能发生在其他器官系统,以便他们能够及时诊断和治疗任何相关的异常。
    Bilateral radii aplasia with the presence of both thumbs and episodes of low platelets count are the main characteristics of thrombocytopenia with absent syndrome, which is an unusual birth disorder, with an incidence of 0.42\\100 000 population.
    UNASSIGNED: The authors reported a case of a 6-month-old baby girl who experienced thrombocytopenia at the age of 6 months for the first time, as a result of cow\'s milk being introduced for 45 days with chronic diarrhea and growth failure. She had a deviation of the axis of the hand laterally, and a bilateral absent of radii with the presence of both thumbs. In addition, she had abnormal psychomotor development, marasmus case manifestations.
    UNASSIGNED: Our aim in publishing the current case report is that clinicians caring for patients with thrombocytopenia with absent syndrome will be aware of the myriad of complications, which may occur in the other organ systems so that they can promptly diagnose and treat any associated abnormalities.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    尽管广泛水解配方奶粉被广泛接受用于长期管理牛乳蛋白过敏(CMPA),缺乏关于其短期疗效的证据.本研究的目的是调查被诊断为CMPA的婴儿的短期症状变化(3-6周内),并在随后的医生就诊时使用含有鼠李糖乳杆菌的广泛水解配方进行管理。医疗保健提供者正在治疗202名六个月以下被诊断患有CMPA的患者,已完成去识别调查,然后在这项前瞻性研究中进行了分析。在他们第一次访问之后,患者开始使用广泛水解配方,他们的基线症状以0-3的严重程度评分。然后在下次随访时对患者进行重新评估,以评估症状严重程度的变化。该研究发现,胃肠道的改善具有统计学意义(93%),皮肤(83%),呼吸(73%),和未分类的症状(90%)。这些症状改善在不同的随访期间是一致的。这项研究是在美国进行的最大的前瞻性分析,评估使用广泛水解配方奶粉在六个月以下婴儿中CMPA症状严重程度的短期变化。这些发现表明,广泛水解配方与临床症状缓解有关,这在下一次后续访问中往往是显而易见的。然而,需要更多的随机对照试验来验证这些结果.
    Although extensively hydrolyzed formula is widely accepted for managing cow\'s milk protein allergy (CMPA) long-term, there is a lack of evidence on its short-term efficacy. This study\'s objective was to investigate the short-term symptom changes (within 3-6 weeks) of infants diagnosed with CMPA and managed with extensively hydrolyzed formula containing Lactobacillus rhamnosus at their subsequent physician visit. Healthcare providers treating 202 patients diagnosed with CMPA under six months old completed de-identified surveys, which were then analyzed in this prospective study. After their first visit, the patients were started on extensively hydrolyzed formula, and their baseline symptoms were scored on a severity scale of 0-3. Patients were then reevaluated at their next follow-up visit to assess changes in symptom severity. The study found statistically significant improvements in gastrointestinal (93%), skin (83%), respiratory (73%), and uncategorized symptoms (90%). These symptom improvements were consistent across different follow-up visit durations. This study is the largest prospective analysis conducted in the United States evaluating short-term change in CMPA symptoms severity in infants under six months old using extensively hydrolyzed formula. These findings suggest that extensively hydrolyzed formula is associated with clinical symptom relief, which is often noticeable by the next follow-up visit. However, additional randomized control trials are needed to validate these results.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    UNASSIGNED: Cow\'s Milk Protein Allergy (CMPA) is the most common food allergy in children. The reaction is classified into IgE-mediated immediate reaction and delayed-onset, according to the underlying immune mechanism, and hence, the timing of the symptoms. Case reports suggest that children, with delayed CMPA reactions on elimination diet, may develop severe immediate reactions on reintroduction.
    UNASSIGNED: The objective of this study was to evaluate the incidence and the risk factors of developing immediate reactions to milk and dairy products in children with CMPA whose initial presentations were of delayed type.
    UNASSIGNED: A retrospective chart review of children, aged 0-12 years, presented with delayed type CMPA reactions to the allergy-clinical immunology clinics, was performed. The diagnosis was made clinically, and with appropriate allergy tests when indicated.
    UNASSIGNED: Sixty children were included. Males:female ratio was 1.7:1. Family history of atopy was in 72%, and 57% had personal history of atopy. Sixty percent were not breast fed. The most common concomitant food allergy was egg. The most common initial presentation was diarrhea without protein loss or bleeding followed by exacerbation of atopic dermatitis upon exposure to dairy products. Immediate reactions developed in 21.6% upon re-exposure. There were significant associations with concomitant food allergy (OR 56.6 (3.15-1016.1) P<0.0001), especially eggs (OR 12.85 (3.09-53.5) P<0.01).
    UNASSIGNED: Children with CMPA, who present with delayed-type allergic reactions, may be at a significant risk of developing immediate reactions upon reintroduction. Evaluation of possible IgE-mediated allergic reactions before reintroduction may be advisable.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    建议将广泛水解的配方食品(eHFs)用于非纯母乳喂养婴儿的牛奶蛋白过敏(CMPA)的饮食管理。研究表明,eHF之间的肽谱不同。这篇简短的综述旨在强调肽的变异性及其影响变应原性的能力,并可能通过不同的eHFs诱导耐受性。eHFs之间的差异由蛋白质部分(酪蛋白或乳清)的来源决定,肽的大小分布图和残留的β-乳球蛋白,这是人类婴儿牛乳中最具免疫原性和过敏性的蛋白质,因为它不存在于人类母乳中。这些差异来自水解过程,该过程导致患有CMPA的受试者对牛奶过敏原表位的IgE反应性可变,并引起Th1,Th2和促炎细胞因子反应的差异。它们对肠道屏障完整性也有不同的影响。结果表明,一种特定的eHF-酪蛋白由于其残留的过敏原表位含量低而具有最小的过敏原潜力,并且通过其对粘蛋白5AC的作用对恢复肠道屏障完整性表现出最大的作用。人肠上皮细胞中的occludin和ZonaOccludens-1。它还增加了致耐受性细胞因子II-10和IFN-γ的产生。此外,最近的研究记录了可选的功能性成分的有希望的效果,如pre,益生菌和合生元对牛奶过敏的管理和耐受性的诱导,部分通过诱导产生短链脂肪酸。这篇综述强调了残留致敏性的差异,肽大小分布,任选功能成分的存在和几个特征良好的eHFs的整体功能,这可能影响CMPA的管理和诱导对牛乳蛋白免疫耐受的能力。
    Extensively hydrolyzed formulas (eHFs) are recommended for the dietary management of cow\'s milk protein allergy (CMPA) in non-exclusively breastfed infants. Studies show that peptide profiles differ between eHFs. This short review aims to highlight the variability in peptides and their ability to influence allergenicity and possibly the induction of tolerance by different eHFs. The differences between eHFs are determined by the source of the protein fraction (casein or whey), peptide size-distribution profile and residual β-lactoglobulin which is the most immunogenic and allergenic protein in bovine milk for human infants as it is not present in human breastmilk. These differences occur from the hydrolyzation process which result in variable IgE reactivity against cow\'s milk allergen epitopes by subjects with CMPA and differences in the Th1, Th2 and pro-inflammatory cytokine responses elicited. They also have different effects on gut barrier integrity. Results suggest that one particular eHF-casein had the least allergenic potential due to its low residual allergenic epitope content and demonstrated the greatest effect on restoring gut barrier integrity by its effects on mucin 5AC, occludin and Zona Occludens-1 in human enterocytes. It also increased the production of the tolerogenic cytokines Il-10 and IFN-γ. In addition, recent studies documented promising effects of optional functional ingredients such as pre-, pro- and synbiotics on the management of cow\'s milk allergy and induction of tolerance, in part via the induction of the production of short chain fatty acids. This review highlights differences in the residual allergenicity, peptide size distribution, presence of optional functional ingredients and overall functionality of several well-characterized eHFs which can impact the management of CMPA and the ability to induce immune tolerance to cow\'s milk protein.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号